| Jason Scott Slakter |
Founder of Digital Angiography Reading Center and SKS Ocular LLC, Jason Scott Slakter currently is President, Chief Executive Officer & Director at Ohr Pharmaceutical, Inc. He is also on the board of Digital Angiography Reading Center and Member of American Society of Retinal Specialists, Member of The Retina Society, Member of American Ophthalmological Society, Professor-Ophthalmology at New York University School of Medicine, Partner at Vitreous Retina Macula Consultants of New York and Member of Macula Society.
In his past career he occupied the position of Chief Medical Officer at Potentia Pharmaceuticals, Inc. and Chief Executive Officer of SKS Ocular LLC. |
| Glenn L. Stoller |
Founder of SKS Ocular LLC, Glenn L. Stoller currently is Chief Scientific Officer of Ohr Pharmaceutical, Inc. He is also Member of American Society of Retinal Specialists and Member of The Retina Society.
In the past he occupied the position of Chief Scientific Officer of SKS Ocular LLC.
He received a doctorate from New York University. |
| Michael A. Ferguson |
Founder of Ferguson Strategies LLC, Michael A. Ferguson presently occupies the position of Chairman for Ohr Pharmaceutical, Inc., Chairman & Chief Executive Officer for Ferguson Strategies LLC and Chairman-Commissioners Board at New Jersey Sports & Exposition Authority. Mr. Ferguson is also on the board of NanoVibronix, Inc. and Independent College Fund of New Jersey.
He received a graduate degree from Georgetown University and an undergraduate degree from the University of Notre Dame. |
| Marlene Modi |
Currently, Marlene Modi is Vice President-Preclinical & Regulatory Affairs at Ohr Pharmaceutical, Inc.
Dr. Modi previously held the position of Vice President-PreClinical Development at Optherion, Inc., Director-Clinical Pharmacology at Hoffmann-La Roche, Inc. and Senior Director-Clinical Pharmacology at Eyetech Pharmaceuticals, Inc.
Dr. Modi received an undergraduate degree from the University of Houston and a doctorate from State University of New York at Buffalo. |
| Orin Zvi Hirschman |
Mr. Orin Z. Hirschman is Chief Executive Officer at AIGH Capital Management LLC and a Principal at Aigh Investment Partners LP.
Mr. Hirschman was previously employed as Vice President by 8x8, Inc. He also worked at Adam Smith Capital Management LLC, D.H. Blair & Co., Inc., and LightPath Technologies, Inc.
He received his undergraduate degree from Touro College and an MBA from The Leonard N Stern School of Business. |
| June Sherie Almenoff |
Currently, June Sherie Almenoff holds the position of Chief Scientific Officer at RedHill Biopharma Ltd. She is also on the board of Brainstorm Cell Therapeutics, Inc., TiGenix NV, RDD Pharma Ltd. (former Chairman) and Ohr Pharmaceutical, Inc.
She previously was Chief Operating & Medical Officer at Innovate Biopharmaceuticals, Inc., President, CEO, Director & Chief Medical Officer at Furiex Pharmaceuticals, Inc., Vice President-Clinical Safety & Pharmacovigilance at GlaxoSmithKline LLC and Member of Infectious Diseases Society of America.
She received an undergraduate degree from Smith College and a doctorate from Icah School of Medicine at Mount Sinai. |
| Thomas M. Riedhammer |
Thomas M. Riedhammer is on the board of Sirion Holdings, Inc., Ohr Pharmaceutical, Inc. and DepYmed, Inc. In his past career he was President for PACO Research Corp., Chairman of Sirion Therapeutics, Inc., Senior Vice President & Chief Technical Officer at Bausch + Lomb, Inc., Chief Operating Officer for Presby Corp, Corporate Vice President at Paco Pharmaceutical Services, Inc., Chairman at Prevent Blindness Florida and Secretary for Sjögren's Syndrome Foundation, Inc.
He received a doctorate and an undergraduate degree from State University of New York at Buffalo. |
